
Insulin
Insulin Cost and Affordability
March 16, 2023: Sanofi announces insulin price cuts.
“The American Diabetes Association (ADA) is the leading voice advocating for insulin affordability and is working to ensure that all people with diabetes have access to the care they need. The ADA has led the charge to enact cost-sharing limits on insulin in 22 states and D.C., and the first-ever federal copay cap in Medicare. We are encouraged that all of the major manufacturers have taken steps to make insulin more affordable, but the fight is not over. We will continue advocating for efforts in Congress and states across the country to ensure insulin is affordable to everyone with diabetes who relies on it to survive.”- Lisa Murdock, ADA Chief Advocacy Officer
March 14, 2023: Novo Nordisk announces insulin price reduction.
“The American Diabetes Association® (ADA) is the leading voice advocating for insulin affordability and is working to ensure that all people with diabetes have access to the care they need. The ADA has led the charge to enact cost-sharing limits on insulin in 22 states and D.C., and now the first-ever federal copay cap in Medicare. We are pleased that more manufacturers are continuing to take steps to make insulin more affordable, and we hope others follow suit. ADA will keep working to make sure drug rebates are not inflating costs for patients at the pharmacy counter, and we will continue to support efforts to provide affordable insulin to everyone with diabetes who relies on it to survive.” - Lisa Murdock, ADA Chief Advocacy Officer
March 1, 2023: Lilly announces cost-sharing limits on insulin.
“The American Diabetes Association (ADA) is the leading voice advocating for insulin affordability and is working to ensure that all people with diabetes have access to the care they need. We applaud Eli Lilly for taking the important step to limit cost-sharing for its insulin, and we encourage other insulin manufacturers to do the same. While we have been able to help achieve significant progress on the issue of insulin affordability, including Medicare’s new out-of-pocket cost cap on insulin, state copay caps, and patient assistance developments from insulin manufacturers, we know that our work is not done. We will work to ensure that Eli Lilly’s patient assistance program is benefiting patients as intended and continue the fight so that everyone who needs insulin has access.” — Charles “Chuck” Henderson, CEO of the American Diabetes Association
Join Us in the Fight for Affordable Insulin!
There have been significant recent developments including Medicare’s new monthly and annual out-of-pocket caps on insulin and prescription drugs, state enacting co-pay caps on insulin, other policy reforms, and patient assistance programs through insulin manufacturers.
We know you may have questions about what this means for you. Don’t worry, we’ve got you covered. Below is information about out-of-pocket caps for insulin and how you can take advantage of the new cost-sharing limits based on the type of health insurance coverage you have: